Lineage Cell Therapeutics, Inc.
LCTX
$0.4817
-$0.0183-3.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 13.39% | 12.81% | -9.82% | -0.42% | 18.22% |
| Total Depreciation and Amortization | -11.99% | -8.26% | -5.52% | -3.33% | -4.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.17% | -6.77% | 52.01% | -4.67% | -61.63% |
| Change in Net Operating Assets | 18.86% | 43.89% | 74.23% | 63.43% | -157.76% |
| Cash from Operations | 19.16% | 26.21% | 29.65% | 27.99% | -2,797.45% |
| Capital Expenditure | 16.17% | 48.68% | 55.46% | 5.59% | -63.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -103.70% | -84.18% | 131.27% | 204.57% | 203.01% |
| Cash from Investing | -104.97% | -84.82% | 126.53% | 200.97% | 200.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -6.00% | -13.04% | -45.95% | -68.75% |
| Issuance of Common Stock | 437.84% | 108.59% | 146.91% | 6,409.69% | 743.34% |
| Repurchase of Common Stock | 90.25% | -500.00% | -500.00% | -382.61% | -1,288.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 140.95% | -90.88% | -112.68% | -100.00% |
| Cash from Financing | 458.26% | 115.16% | 122.19% | 1,725.27% | 293.57% |
| Foreign Exchange rate Adjustments | 62.00% | 126.56% | 76.11% | 76.37% | 71.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -56.93% | -155.11% | 88.41% | 144.90% | 154.25% |
